89 related articles for article (PubMed ID: 694481)
1. [Antiestrogens: a new endocrine treatment possibility in metastasizing breast neoplasms. Experiences of the Swiss Cooperative Cancer Study Group with tamoxifen].
Jungi WF; Alberto P; Wagenknecht L; Cavalli F; Martz G; Brunner KW
Schweiz Med Wochenschr; 1978 Aug; 108(34):1317-21. PubMed ID: 694481
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogen-induced remissions in stage IV breast cancer.
Manni A; Trujillo J; Marshall JS; Pearson OH
Cancer Treat Rep; 1976 Oct; 60(10):1445-50. PubMed ID: 1021225
[TBL] [Abstract][Full Text] [Related]
3. [Hormone therapy of metastasizing breast cancer with tamoxifen].
Köhler A; Noss W; Dobberstein N; Stoltmann R; Pohl J
Z Gesamte Inn Med; 1986 Jan; 41(1):6-9. PubMed ID: 3953121
[TBL] [Abstract][Full Text] [Related]
4. [Anti-oestrogen treatment of metastasising carcinoma of the breast (author's transl)].
Henningsen B; Amberger H
Dtsch Med Wochenschr; 1977 May; 102(19):713-6. PubMed ID: 870301
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
6. [The treatment of metastasizing breast carcinoma using antiestrogens].
Pienkowski T; Palucka-Bartoszewicz A; Pienkowska F; Zborzil J; Schneider J
Wien Med Wochenschr; 1991; 141(13):294, 297-300. PubMed ID: 1926878
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of the antioestrogenic agent tamoxifen in the treatment of metastatic breast cancer (author's transl)].
Szepesi T; Czech W
Wien Klin Wochenschr; 1978 Feb; 90(4):133-41. PubMed ID: 625990
[TBL] [Abstract][Full Text] [Related]
8. [A case of advanced breast cancer with multiple organ metastases successfully treated by tamoxifen].
Shiba E; Kobayashi T; Takeda T; Miya A; Kawano I; Takai S; Mori T
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2255-8. PubMed ID: 1444494
[TBL] [Abstract][Full Text] [Related]
9. Clinical experiences with tamoxifen for estrogen receptor blocking therapy in metastatic breast cancer.
Henningsen B
Prog Clin Biol Res; 1977; 12():479-82. PubMed ID: 918118
[No Abstract] [Full Text] [Related]
10. Tamoxifen therapy of metastatic breast cancer.
Manni A
J Lab Clin Med; 1987 Mar; 109(3):290-9. PubMed ID: 2950193
[TBL] [Abstract][Full Text] [Related]
11. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Rose C; Kamby C; Mouridsen HT; Bastholt L; Brincker H; Skovgaard-Poulsen H; Andersen AP; Loft H; Dombernowsky P; Andersen KW
Breast Cancer Res Treat; 1986; 7 Suppl():S45-50. PubMed ID: 3527306
[TBL] [Abstract][Full Text] [Related]
12. [Additive treatment of metastasizing breast cancer with special reference to postmenopausal age (results of a randomized study)].
Firusian N; Schietzel M
Strahlentherapie; 1976 Sep; 152(3):235-47. PubMed ID: 968923
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
14. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
15. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Nicolini A; Carpi A
Biomed Pharmacother; 2005 Jun; 59(5):253-63. PubMed ID: 15913946
[TBL] [Abstract][Full Text] [Related]
16. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogen treatment of breast cancer: an overview.
Pearson OH; Manni A; Arafah BM
Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
[TBL] [Abstract][Full Text] [Related]
18. [Hormone therapy of breast cancer].
Maass H
Med Welt; 1976 May; 27(21):1047-51. PubMed ID: 180375
[TBL] [Abstract][Full Text] [Related]
19. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
20. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
Kaye SB; Woods RL; Fox RM; Coates AS; Tattersall MH
Cancer Res; 1982 Aug; 42(8 Suppl):3445s-3447s. PubMed ID: 6177404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
